Brought to you by 
Resolve Therapeutics closes $5.8mm Series B round for lupus compound trials
03 Dec 2012
Executive Summary
Two-year-old Resolve Therapeutics LLC (developing a new treatment for systemic lupus erythematosus) has raised $5.8mm in its Series B round. The funds, provided by returning backers New Science Ventures (lead) and Easton Capital along with new investor WRF Capital, will support upcoming Phase I studies for the company's lupus candidate RSLV132. The first trial is expected to begin in mid-2013.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Resolve Therapeutics closes $5.8mm Series B round for lupus compound trials
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice